Article
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet.
Blood - 4 Aug 2011
Soverini Simona, Hochhaus Andreas, Nicolini Franck E, Gruber Franz, Lange Thoralf, Saglio Giuseppe, Pane Fabrizio, Müller Martin C, Ernst Thomas, Rosti Gianantonio, Porkka Kimmo, Baccarani Michele, Cross Nicholas C P, Martinelli Giovanni
Abstract excerpt
Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations aimed to rationalize the use of BCR-ABL mutation testing in chronic myeloid leukemia have been compiled by a panel of experts appointed by the European LeukemiaNet (ELN) and European Treatment and Outcome Study and are here reported. Based on a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.